B6N(B6)-Trem1tm1.2Cmuel/Orl

Status

Available to order

EMMA IDEM:15810
Citation informationRRID:IMSR_EM:15810 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameB6N(B6)-Trem1tm1.2Cmuel/Orl
Alternative nameC57BL/6NTac-Trem1tm1.2Cmuel
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolTrem1tm1.2Cmuel
Gene/Transgene symbolTrem1

Information from provider

ProviderChristoph Mueller
Provider affiliationInstitute of Tissue Medicine and Pathology, University of Bern
Additional ownerProf. Mirjam Schenk, Institute of Tissue Medicine and Pathology, University of Bern, Switzerland
Genetic informationTrem1 knock-out. Weber B., Mueller C. in collaboration with TaconicArtemis GmbH. Electroporation of a targeting vector encoding mouse Trem1 exon 2 flanked by loxP sites into a C57BL/6NTac embryonic stem cell line. Injection of positive clones into BALB/c blastocytes and transfer to NMRI pseudopregnant females. Breeding of chimeric offspring to C57BL/6 mice. Trem1+/flox (C57BL/6-Trem1tm1821_33.1Arte) mice were further bred with mice carrying the cre recombinase under the control of the Gt(ROSA)26Sor locus to obtain systemic deletion of one Trem1 allele. Trem1+/- x cre+/- mice were interbred to achieve deletion of Cre and to obtain wild-type (Trem1+/+) and heterozygous and homozygous Trem1-deficient mice (Weber B et al., PLoS Pathog. 2014 Jan;10(1).
Phenotypic informationHomozygous:
Animals are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. No increased morbidity or mortality in naive mice. In various models of inflammation and infection, the line even showed highly attenuated disease. Full welfare assessment was performed at the University of Bern. Continuous breeding of the line between 2009 and 2014 has indicated no abnormalities in comparison to C57BL/6JRj control mice (normal fertility, no increased morbidity or mortality). Since the Trem1 knock-out line even appears to be protected in various models of inflammation and infection, the line is considered not strained.

Heterozygous:
Animals are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. No increased morbidity or mortality in naive mice. In various models of inflammation and infection, the line even showed highly attenuated disease. Full welfare assessment was preformed at the University of Bern. Continuous breeding of the line between 2009 and 2014 has indicated no abnormalities in comparison to C57BL/6JRj control mice (normal fertility, no increased morbidity or mortality).
Breeding historyTrem1tm1.1Cmuel crossed to C57BL/6-Gt(ROSA)26Sortm16(Cre)Arte (TaconicArtemis) to generate the Trem1 knock-out mouse strain. The Trem1 knock-out mouse strain was generated and maintained on a C57BL/6NTac background and kept by homozygous breeding. The line has been continuously bred at the University of Bern (over 20 generations) and was cryopreserved in 2013/2014.
References
  • TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance.;Weber Benjamin, Schuster Steffen, Zysset Daniel, Rihs Silvia, Dickgreber Nina, Schürch Christian, Riether Carsten, Siegrist Mark, Schneider Christoph, Pawelski Helga, Gurzeler Ursina, Ziltener Pascal, Genitsch Vera, Tacchini-Cottier Fabienne, Ochsenbein Adrian, Hofstetter Willy, Kopf Manfred, Kaufmann Thomas, Oxenius Annette, Reith Walter, Saurer Leslie, Mueller Christoph, ;2014;PLoS pathogens;10;e1003900; 24453980
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedno

Information from EMMA

Archiving centreCNRS-TAAM – Typing and Archiving of Animal Models, Orléans, France
Animals used for archivinghomozygous C57BL/6NTac males

Disease and phenotype information

IMPC phenotypes (gene matching)
  • increased anti-nuclear antigen antibody level / IMPC

Literature references

  • TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance.;Weber Benjamin, Schuster Steffen, Zysset Daniel, Rihs Silvia, Dickgreber Nina, Schürch Christian, Riether Carsten, Siegrist Mark, Schneider Christoph, Pawelski Helga, Gurzeler Ursina, Ziltener Pascal, Genitsch Vera, Tacchini-Cottier Fabienne, Ochsenbein Adrian, Hofstetter Willy, Kopf Manfred, Kaufmann Thomas, Oxenius Annette, Reith Walter, Saurer Leslie, Mueller Christoph, ;2014;PLoS pathogens;10;e1003900; 24453980

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).